Abstract
Macrocyclic peptides can interfere with challenging biomolecular targets including protein‒protein interactions. Whereas there are various approaches that facilitate the identification of peptide-derived ligands, their evolution into higher affinity binders remains a major hurdle. We report a virtual screen based on molecular docking that allows the affinity maturation of macrocyclic peptides taking non-natural amino acids into consideration. These macrocycles bear large and flexible substituents which usually complicate the use of docking approaches. A virtual library containing more than 1400 structures was screened against the target focusing on docking poses with the core structure resembling a known bioactive conformation. Based on this screen, a macrocyclic peptide (22) involving two non-natural amino acids was evolved showing increased target affinity and biological activity. Predicted binding modes were verified by X-ray crystallography. The presented workflow allows the screening of large macrocyclic peptides with diverse modifications thereby expanding the accessible chemical space and reducing synthetic efforts.
Original language | English |
---|---|
Pages (from-to) | 8982-8988 |
Number of pages | 7 |
Journal | Journal of Medicinal Chemistry |
Volume | 60 |
Issue number | 21 |
Early online date | 13 Oct 2017 |
DOIs | |
Publication status | Published - 13 Oct 2017 |
Funding
We are grateful for support from AstraZeneca, Bayer CropScience, Bayer HealthCare, Boehringer Ingelheim, Merck KGaA, and the Max-Planck-Society. O.K. is funded by the German Federal Ministry for Education and Research (Medizinische Chemie in Dortmund, Grant No. BMBF 1316053). T.N.G. thanks the Deutsche Forschungsgemein-schaft (DFG; Emmy Noether program GR3592/2-1) and the European Reasearch Council (ERC; ERC starting grant, no. 678623). This work was supported by the Collaborative Research Centre 1093, funded by the Deutsche Forschungsge-meinschaft (DFG). We appreciate IT support by C. Schwittek (MPI Dortmund).
Funders | Funder number |
---|---|
Max-Planck-Society | |
Medizinische Chemie in Dortmund | BMBF 1316053 |
AstraZeneca | |
Boehringer Ingelheim | |
Bayer CropScience | |
Merck KGaA | |
Horizon 2020 Framework Programme | 678623 |
European Research Council | |
Bayer HealthCare | |
Deutsche Forschungsgemeinschaft | GR3592/2-1 |
Bundesministerium für Bildung und Forschung |
Keywords
- Journal Article